Squarepoint
TYRA icon

Squarepoint’s Tyra Biosciences TYRA Stock Holding History

Squarepoint’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.04M Buy
63,805
+43,311
+211% +$1.43M ﹤0.01% 2334
2026
Q1 		$785K Sell
20,494
-33,930
-62% -$1.1M ﹤0.01% 2978
2025
Q4 		$1.43M Buy
54,424
+42,210
+346% +$775K ﹤0.01% 2315
2025
Q3 		$171K Sell
12,214
-19,194
-61% -$219K ﹤0.01% 3989
2025
Q2 		$301K Buy
+31,408
New +$298K ﹤0.01% 3683
2025
Q1 		– Sell
-18,216
Closed -$253K – 5431
2024
Q4 		$253K Buy
+18,216
New +$331K ﹤0.01% 4287

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Squarepoint's TYRA Position: Q2 2026 in Review

Squarepoint increased its Tyra Biosciences (TYRA) stake by 211% in Q2 2026, buying an estimated $1.43M and bringing the position to 63,805 shares worth $2.04M. The position accounts for ﹤0.01% of the portfolio, ranked #2334.

Squarepoint first reported a position in TYRA in Q4 2024 and has held it in 6 quarters since. 169 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • Squarepoint held 63,805 shares of Tyra Biosciences worth $2.04M as of Q2 2026.
  • Squarepoint bought 43,311 Tyra Biosciences shares in Q2 2026, an estimated $1.43M.
  • Tyra Biosciences made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2334 holding.
  • Squarepoint first reported a position in Tyra Biosciences in Q4 2024 and has held it in 6 quarters since.
  • 169 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.